Canada's CADTH conditionally recommends Novartis Lutathera for midgut neuroendocrine tumors

Key Insights

  • pERC conditionally recommends the reimbursement of inLu-Dotatate (Lutathera) for the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut neuroendocrine tumours (NETs) whose disease has progressed on a somatostatin analogue and is unresectable if the following conditions are met:
  1. cost-effectiveness being improved to an acceptable level
  2. feasibility of adoption (budget impact) being addressed
  3. capacity for jurisdictions to have the infrastructure in place to implement 177 Lu-Dotatate.
  • "pERC made this recommendation because it was satisfied that there is a net clinical benefit of 17Lu-Dotatate in adult patients with progressed somatostatin receptor-positive midgut NETs compared with octreotide LAR based on a statistically significant and clinically meaningful improvement in progression-free survival (PFS)"
  • "Furthermore, 17Lu-Dotatate is associated with manageable toxicities and no detriment in quality of life (QoL) compared with octreotide LAR"
  • Pricing concerns: "pERC noted that at the submitted price, 177Lu-Dotatate cannot be considered cost-effective compared with octreotide LAR in patients with SSR+ midgut NETs"
  • Budget impact concerns: "pERC highlighted that the potential budget impact of 17Lu-Dotatate for patients with progressed somatostatin receptor-positive midgut NETs is grossly underestimated and will be substantial due to the high cost of the therapy and the number of eligible patients for this treatment"
  • Not recommended for hindgut and foregut: "pERC does not recommend reimbursement of 177Lu-Dotatate in patients with SSR+ foregut and hindgut NETs whose disease has progressed and is unresectable"

NOVEL Health Strategies Team has won more than 15 awards and nominations

NOVEL Health Strategies Team has led and co-authored 150+ Peer Reviewed Studies